Pregabalin and gabapentin treatment in MS patients: Clinical experiences and therapeutic implications

Multiple Sclerosis (MS) is a chronic, progressive autoimmune disease of the CNS with a heterogenic clinical presentation. Patients suffer from a variety of symptoms leading to disability and a loss of life's quality. Besides a basic immunomodulatory therapy, many patients receive additional treatment which specifically addresses symptoms such as bladder dysfunction, daytime sleepiness, spasticity or sensory impairment. To treat paresthesia or paroxysmal pain, pregabalin (PGB) and gabapentin (GBP) are regularly prescribed. Both substances are structurally related to the neurotransmitter γ-aminobutyric acid (GABA)…